Acute liver failure

Journal of Clinical Gastroenterology

Volumn 33, Issue 3, 2001, Pages 191-198

  Gill, Riaz Q ^a   Sterling, Richard K ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Acute liver failure; Fulminant hepatic failure; Therapy

Indexed keywords

ACETYLCYSTEINE; PARACETAMOL; TOXIN;

ACUTE KIDNEY FAILURE; BRAIN EDEMA; CLINICAL FEATURE; DRUG OVERDOSE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPOGLYCEMIA; INTOXICATION; LIVER FAILURE; LIVER TRANSPLANTATION; METABOLIC DISORDER; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEPSIS; SIDE EFFECT; VIRUS HEPATITIS;

BRAIN EDEMA; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; MULTIPLE ORGAN FAILURE; PROGNOSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0034892970     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200109000-00005     Document Type: Review

References (62)

1. The management of fulminant hepatic failure
2. Fulminant and subfulminant hepatic failure: Definition and causes
3. Fulminant hepatic failure: Summary of workshop
4. Pediatric aspects of acute liver failure
5. Use of liver transplantation in patients with acute liver failure
6. Protective agent for acetaminophen overdosage
7. Baffling hepatitis virus is isolated, scientists says
8. Could an endogenous benzodiazepine ligand contribute to HE?
9. Sub-clinical seizure activity and prophylactic phenytoin administration in ALF
10. Cerebral edema: A major complication of massive hepatic necrosis
11. Pathophysiology of cerebral edema in fulminant hepatic failure
12. Brain edema and porto-systemic encephalopathy
13. Fulminant hepatic failure and orthotopic liver transplantation
14. Monitoring and treatment of intracranial hypertension
15. Coagulation factor V as prognostic indicator in fulminant hepatic failure
16. Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced hepatic failure: Relation to other prognostic factors
17. Activation of the fibrinolytic system in patients with fulminant liver failure
18. Early indicators of prognosis in FHF
19. Frequency of renal impairment in paracetamol overdose compared with other causes of acute liver damage
20. The systemic inflammatory response syndrome in acute liver failure
21. Multiple organ failure syndrome in the 1990s
22. Multiple organ failure after liver transplantation
23. Fulminant hepatic failure, endogenous endotoxemia, and multiple systems organ failure
24. Acute liver failure: Clinical features, outcome analysis and applicability of prognostic criteria
25. The APACHE II prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults
26. Earlier identification of patients at risk from acetaminophen induced acute liver failure
27. Criteria for emergency liver transplantation with acute viral hepatitis and factor V level >50% of normal: A prospective study
28. Relation of alpha-fetoprotein in acute hepatitis to severity and prognosis
29. Predicting survival in fulminant hepatic failure using serum Gc protein concentrations
30. Immunonephelometric quantification of group-specific component protein in patients with acute liver failure
31. The role of transjugular liver biopsy in fulminant hepatic failure: Relationship to other prognostic indicators
32. Liver biopsy and prognosis in acute liver failure
33. Difficult management problems in fulminant hepatic failure
34. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine
35. Improvement in outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine
36. Cerebral blood flow and metabolism in fulminant hepatic failure
37. Improvement by acetylcysteine of hemodynamic and oxygen transport in fulminant hepatic failure
38. Treatment of hepatic encephalopathy
39. Flumazenil for hepatic coma
40. Advantages of ICP monitoring in patients with fulminant hepatic failure
41. Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure
42. Early changes in coagulation following a paracetamol overdose and a controlled trial of FFP
43. Perioperative management of fulminant and subfulminant hepatic failure with therapeutic plasmapheresis
44. Treatment of fulminant hepatic failure with insulin and glucagon, a randomized controlled trial
45. Treatment of fulminant hepatic failure with intravenous prostaglandin E1
46. A double blinded randomized trail of hydrocortisone in acute hepatic failure
47. Clinical experience with charcoal and resin hemoperfusion
48. Benefits and dangers of plasma exchange in patients with fulminant hepatic failure
49. Plasmapheresis in hepatic coma
50. Artificial liver: States of the art
51. Bioartificial liver in the treatment of hepatic failure
52. Pilot-controlled trial of extracorporeal liver assist device in acute liver failure
53. Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase 1 clinical trial
54. Hepatocyte transplantation as a bridge to OLT in terminal liver failure
55. Hepatocyte transplantation in patients with liver cirrhosis
56. Liver transplantation: Living-related, liver cell transplant, and xenotransplantation
57. Liver transplantation for fulminant hepatic failure
58. Pretransplantation clinical status and outcome of emergency transplantation for acute liver failure
59. Successful living related transplantation in adults with fulminant hepatic failure
60. Emergency living related adult to adult transplantation for fulminant liver failure
61. Living related transplantation for acute liver failure in children
62. Living related transplantation for fulminant hepatic failure